Guangzhou Anti-Cancer Association Establishes Professional Committee for Precision Cancer Diagnosis and Treatment and Holds Inaugural Academic Conference

On September 19, 2026, the inaugural meeting of the Professional Committee for Precision Cancer Diagnosis and Treatment of the Guangzhou Anti-Cancer Association and its first academic conference were held in Guangzhou. Specialists in breast cancer, lung cancer, liver cancer, and nasopharyngeal carcinoma, as well as precision radiation therapy, brain metastases, and other areas of oncology, gathered to exchange insights on advances in precision cancer diagnosis and treatment, decision-making in complex clinical cases, and multidisciplinary collaboration. Participants included Liao Ning, Ma Dong, and other specialists with extensive experience in cancer diagnosis and treatment, as well as clinical experts from Jinshazhou Hospital.
From the early planning stages through the inaugural academic conference, Jinshazhou Hospital remained actively involved in the Committee’s academic and clinical activities and collaboration. Clinical experts from the hospital also participated in the conference’s academic discussions and exchanges. For Jinshazhou Hospital, the “precision diagnosis and treatment” and “multidisciplinary collaboration” discussed at the conference are not merely academic concepts—they are already part of everyday clinical practice, from case evaluation to treatment decision-making and patient care.

Figure 1. Professional Committee Establishment and Flag Presentation. Group Photo

In his address, Professor Liu Yimin, the newly elected Chair of the Committee, noted that precision cancer diagnosis and treatment is inherently multidisciplinary, requiring collaboration among specialists in medical oncology, surgery, radiation oncology, pathology, radiology, laboratory medicine, translational research, and other fields. Going forward, the Committee will advance the implementation of standards for precision cancer diagnosis and treatment through regular academic exchange, multidisciplinary collaboration, and the translation of research findings into clinical practice.

Figure 2. Address by Professor Liu Yimin, Chair of the Professional Committee

Five Key Clinical Areas: From Molecular Subtyping to Comprehensive Decision-Making in Complex Cases

Professor Liao Ning of Guangdong Provincial People’s Hospital centered her presentation on the role of molecular pathology in guiding clinical decision-making in breast cancer. Drawing on data from studies in Chinese populations and clinical cases, she discussed molecular subtypes of breast cancer, genetic characteristics, genetic testing, and therapeutic targets, with a focus on how these factors can help clinicians select more appropriate treatment strategies. Her presentation also examined differences between Chinese and Western populations and research into relevant signaling pathways.
Professor Zhang Jing of the First Affiliated Hospital of Sun Yat-sen University discussed advances in the treatment of small cell lung cancer, ranging from current immunotherapies to emerging approaches such as T-cell engagers (TCEs). She also examined their use across different lines of therapy and in patients with brain metastases, as well as strategies for managing adverse events.
Professor Lin Xinqing of the First Affiliated Hospital of Guangzhou Medical University provided a systematic overview of the risk factors, imaging features, underlying mechanisms, and clinical management of immune-related pneumonitis. She also addressed challenging clinical issues including AI-assisted detection, corticosteroid therapy, differentiation from pulmonary infection, steroid resistance, and chronic fibrosis, helping clinicians recognize the complication early and initiate timely management.

Figure 3. Presentation by Professor Liao Ning

Figure 4. Presentation by Professor Lin Xinqing

Professor Cao Mingrong of the First Affiliated Hospital of Jinan University reviewed updates on selective internal radiation therapy in the 2026 guidelines for primary liver cancer. He provided a systematic overview covering eligible patient populations, dosimetry, standardized procedures, and the integration of this approach with surgery and systemic therapy, offering clear guidance for clinical practice and treatment decision-making.
Professor Wang Chengtao of the First Affiliated Hospital of Sun Yat-sen University reviewed developments in the clinical management of nasopharyngeal carcinoma, with a particular focus on the shift from standardized treatment toward risk stratification and more tailored management. Treatment intensity, treatment combinations, and follow-up strategies may differ across risk groups, helping clinicians develop more appropriate treatment plans for individual patients.
Professor Shan Changguo of Jinshazhou Hospital of Guangzhou University of Chinese Medicine discussed clinical approaches to the treatment of brain metastases. Drawing on clinical cases, he explored precision radiation therapy, multidisciplinary collaboration, and individualized treatment. His presentation further underscored one of the conference’s central themes: true precision is not simply about using more advanced technology in isolation, but about combining different approaches appropriately for the right patient at the right stage of treatment.

Figure 5. Presentation by Professor Cao Mingrong

Figure 6. Presentation by Professor Wang Chengtao

Figure 7. Presentation by Professor Shan Changguo

Beyond the Conference: Academic Exchange at Jinshazhou Hospital

For Jinshazhou Hospital of Guangzhou University of Chinese Medicine, the significance of the conference extends beyond hosting a single academic event. Specialists actively engaged in precision cancer diagnosis and treatment regularly participate in outpatient consultations, ward rounds, consultations on complex cases, and MDT discussions at Jinshazhou Hospital. At the same time, clinical experts from the hospital contributed to the development of the Committee and participated in academic exchanges at the conference. This ongoing clinical and academic collaboration allows expertise from different disciplines to directly inform clinical decision-making for patients rather than remain confined to conference presentations.
From academic exchange among specialists to collaborative decision-making in real clinical cases, precision and collaboration—the central themes of the conference—are also key priorities as Jinshazhou Hospital continues to advance comprehensive cancer care. Ultimately, meaningful academic exchange must translate into benefits for patients—bringing new knowledge, technologies, and clinical experience into everyday care and enabling more systematic evaluation and better-informed treatment decisions in complex clinical cases.